摘要
雌激素受体阳性乳腺癌主要表现为对化疗的不敏感和对激素的依赖,因此对于局部晚期雌激素受体阳性乳腺癌患者来说,单纯新辅助化疗难以达到预期效果,而现有临床指南也不推荐新辅助内分泌治疗作为常规治疗方案。为进一步提高雌激素受体阳性乳腺癌患者新辅助治疗阶段的临床疗效,有研究者对新辅助化疗联合新辅助内分泌治疗进行探索,但研究结论存在争议,其中该方案的适宜人群也是难点之一,本文拟围绕月经状态以及Ki-67指数两个角度对该方案的研究进展进行综述。
Estrogen receptor positive breast cancer mainly shows insensitivity to chemotherapy and dependence on hormones. Therefore, for locally advanced estrogen receptor positive breast cancer patients, neoadjuvant chemotherapy alone is difficult to achieve the expected effect, and the existing clinical guidelines do not recommend neoadjuvant endocrinic therapy as a routine treatment. In order to further improve the clinical efficacy of neoadjuvant therapy for estrogen receptor positive breast cancer patients, some researchers have explored neoadjuvent chemical endocrine therapy, but results are controversial. One of the difficulties is to explore the suitable population for this scheme. This article will review the research progress of this scheme from the perspectives of menstrual status and Ki-67 index.
作者
楚人杰
张彦武
CHU Renjie;ZHANG Yanwu(Department of Breast Surgery,the Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《河南医学研究》
CAS
2023年第1期185-189,共5页
Henan Medical Research
基金
河南省医学科技攻关计划(2018020209)。
